logo
logo

Tetra Bio-Pharma Inc. Announces Revised Terms And First Closing Of Financing With Alpha Blue Ocean

Sep 08, 2022•almost 3 years ago
OttawaPharmaceuticalMedicalBiotechnologyHealth Care

Description

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) ( OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the terms of an amended and restated subscription agreement dated September 2, 2022 (the "Amended and Restated Subscription Agreement").

Company Information

Company

Tetra Bio-Pharma Inc.

Location

Ottawa, Ohio, United States

About

Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra's evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.

Related People